Supplemental Table 1: Multivariable regression analysis with and without ETDM patients

Published: 26 February 2020| Version 1 | DOI: 10.17632/9n4fmw9k5m.1
Contributors:
Kimberly Bowerman,
David R. Pearson,
Joyce Okawa,
Victoria P. Werth

Description

This table identifies risk factors for malignancy associated dermatomyositis (DM) within two years of DM diagnosis. Results show that the classic subtype of DM (CDM) and older age at DM diagnosis are independent risk factors for malignancy associated disease within the first two years of disease onset. This table demonstrates that the results are unchanged when early treated DM (ETDM) patients, defined as those treated with systemic immunosuppressants for more than 2 consecutive months within the first 6 months of skin disease onset, are grouped with CDM patients. DM, dermatomyositis; CDM, classic dermatomyositis; CADM, clinically amyopathic dermatomyositis; ETDM, early treated dermatomyositis

Files

Institutions

Corporal Michael J Crescenz VA Medical Center, University of Pennsylvania

Categories

Dermatology, Medical Dermatology, Dermatomyositis

License